Skinvisible, Inc.
29.5.2024 12:32:39 CEST | ACCESS Newswire | Press release
Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Enhanced by Invisicare Topical / Transdermal Delivery System
LAS VEGAS, NV / ACCESSWIRE / May 29, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative pharmaceutical research and development company, announced a major advancement in the battle against obesity. The Company has achieved a significant milestone by officially filing a provisional patent application covering formulations that leverage the Company's proprietary delivery technology Invisicare® for the transdermal administration of obesity drugs. Titled "Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery," this patent filing ushers in a new era of efficient and convenient obesity drug delivery solutions.
The patent application focuses on Invisicare; a patented transdermal delivery technology designed to incorporate CB-1 receptor antagonists and/or GPL-1 receptor agonists, two classes of drugs known for their potential in obesity management, into a lotion that is applied topically to the skin using a metered applicator. Studies have demonstrated the superior transdermal penetration and controlled release of other active compounds using Invisicare's innovative technology; with certain actives exhibiting up to a tenfold increase in transdermal delivery effectiveness. By utilizing Invisicare, Skinvisible aims to not only offer patients a convenient and effective alternative to traditional oral or injectable therapies but to also enhance drug efficacy and potentially significantly reduce side effects as transdermal delivery avoids first-pass metabolism. Additionally, for long-term treatment of obesity, a transdermal delivery system could feasibly provide a convenient method for administering maintenance doses of anti-obesity medications.
The global obesity drug market is poised to exceed $30 billion by 2027, propelled by the escalating prevalence of obesity worldwide and the eagerly anticipated advent of revolutionary anti-obesity medications. Nonetheless, the impediment posed by needles and injections remains a formidable barrier to access and compliance. Skinvisible's proprietary transdermal delivery technology overcomes this obstacle, unlocking the full therapeutic potential of CB-1 and GLP-1 targeting drugs.
"Our transdermal technology has the potential to revolutionize how obesity drugs are administered, granting patients access to potent weight loss medications through the ease and convenience of a metered dose of lotion simply applied to the skin," remarked Terry Howlett, CEO of Skinvisible Pharmaceuticals. "This needle-free approach holds immense promise in enhancing treatment adherence and broadening the accessibility of obesity therapies to countless individuals grappling with weight-related challenges." He added, "This groundbreaking patent application highlights our proficiency in transdermal delivery and underscores our commitment to leveraging this capability to reshape treatment standards."
Skinvisible is actively pursuing strategic partnerships with pharmaceutical and/or biotech companies to facilitate the introduction of the first transdermal obesity therapies to market and to explore the application of its delivery platform across diverse disease domains.
For more information on Skinvisible Pharmaceuticals, partnerships and investment opportunities, please visit www.skinvisible.com or contact info@skinvisible.com.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby including with respect to the possible development of any such products, the acceptance of any such products in the market place, the size of any such markets, the ability of any product candidates to be approved by the U.S. Food and Drug Administration among others. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending March 31, 2024).
###
Contacts:
Strategic Partnerships: Doreen McMorran - doreen@invisicare.com
Corporate Inquiries: info@skinvisible.com Office Number: 702-433-7154 (PST)
SOURCE: Skinvisible, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata Reports Record Second Quarter 2026 Results6.8.2026 22:05:00 CEST | Press release
Revenue Up 58% Year-Over-Year, Beats Consensus by 7% Adjusted EBITDA of $25.4 Million, Beats Consensus by 50% Adjusted Gross Margin Expands to 49% Announces Planned Leadership Transition Effective September 30: Rahul Singhal to Become President and CEO, Jack Abuhoff to Become Executive Chairman NEW YORK, NY / ACCESS Newswire / August 6, 2026 / INNODATA INC. (NASDAQ:INOD) today reported results for the second quarter ended June 30, 2026. Revenue of $92.1 million, representing 58% year-over-year revenue growth. Adjusted Gross Profit of $45.4 million, representing Adjusted Gross Margin of 49%.* Adjusted EBITDA of $25.4 million, or 27.5% of revenue, an increase of $12.1 million from $13.2 million in the same period last year.* Net income of $14.4 million, or $0.43 per basic share and $0.41 per diluted share for the three-month period ended June 30, 2026, compared to net income of $7.2 million, or $0.23 per basic share and $0.20 per diluted share, in the same period last year. Cash, cash eq
Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook6.8.2026 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / August 6, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our") reported record results for the second quarter of 2026. "Through the first half of the year, the business continues to outperform our expectations, driven by exceptional demand across our end-markets and strong conversion of our new business pipeline. Of the approximately $750 million in our pipeline, we secured initial orders that provide visibility to approximately $200 million of revenue over the next five years," said Dirkson Charles, Loar Holdings Chief Executive Officer and Executive Co-Chairman of the Board of Directors. Second Quarter 2026 Net sales of $171.6 million, up 39.4% compared to the prior year's quarter. Net income of $16.7 million, equal to the prior year's quarter. Diluted earnings per share of $0.18 compared to $0.17 for the prior year's quarter. Adjusted EBITDA of $69.4 million up 47.4% compared to the prior year's quarter. Net income
RE Royalties Announces Third Investment in Solaris Energy's Portfolio and Letter of Intent for Expanded Royalty Partnership for a Further US$62.7 Million5.8.2026 12:00:00 CEST | Press release
All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further investment of US$1 million toward the purchase of royalties on a portfolio of Solaris Energy Inc.'s ("Solaris") distributed generation ("DG") solar projects located throughout the United States. The Company also announced that it has entered into a non-binding Letter of Intent ("LOI") of up to US$67.5 million with Solaris to pursue an expanded royalty funding partnership across Solaris' current and future project pipeline. This third tranche payment brings RE Royalties' total investment in royalties over Solaris' portfolio to US$4.8 million. The Company previously funded US$3 million, as announced on January 7, 2026, followed by US$800,000 as announced on February 9, 2026. Solaris' Portfolio consists of 16 distributed generation solar projects totaling approximately 15.2
Kleen Hy-Dro-Gen Inc. Is Pleased to Announce Dual ISO 9001:2015 and TSSA Certifications, Bolstering Operational Quality and Technical Safety Governance5.8.2026 02:10:00 CEST | Press release
Key regulatory and quality management accreditations position the CSE-listed clean energy technology provider for accelerated commercialization and potential major enterprise contracts to manufacture and sell, residential and commercial, Zero Emissions Heating Systems using Hydrogen as a heat energy source. TORONTO, ON / ACCESS Newswire / August 4, 2026 / Kleen-Hy-Dro-Gen Inc. (the "Company") (CSE:KLN) is pleased to announce that it has officially achieved both ISO 9001:2015 Quality Management System certification and regulatory Technical Standards and Safety Authority ("TSSA") certification for its flagship product KLEEN HEAT On-Demand Hydrogen Heating System. These dual accreditations mark a major operational milestone for the Company, establishing independent third-party verification of the Company's quality assurance framework, engineering standards, and regulatory safety compliance across its Kleen Heat technology, advancing the Company's goal of safely utilizing the system in Zer
Innodata Releases the First Stage of Its AI Cyber Training Suite to Enable AI Coding Agents to Write - and Repair - Secure Code4.8.2026 14:30:00 CEST | Press release
Twelve datasets and evaluation systems, built by hand from thousands of real-world security flaws, give model builders and enterprises a proven way to keep AI-generated code from introducing vulnerabilities. NEW YORK, NY / ACCESS Newswire / August 4, 2026 / INNODATA INC. (Nasdaq:INOD) today released the first stage of its AI Cyber Training Suite - twelve datasets and evaluation systems that train AI coding agents to write code that avoids known security flaws, to avoid introducing new ones, and to patch existing vulnerabilities in the software companies already run. The suite addresses what has become a central barrier to trusting AI-written code: the risk that an agent, while adding a feature or modernizing a legacy system, quietly opens a security hole. The AI Cyber Training Suite works across the stack of coding agents - the models, the harnesses, and the tools - to help ensure the code they produce is not just functional, but secure. It is available to model builders and enterprise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom